TABLETTEN ENTHALTEND ELTROMBOPAG OLAMIN

European patent · EP4218732 · In force

Register entry

Publication number
EP4218732
Application number
EP23166852
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 1, 2007
Published
Aug 2, 2023
Granted
Mar 26, 2025
Protection ends at the latest
Jul 31, 2027
Next annual fee due
Aug 31, 2027
IPC classes
A61K 9/14 (2006.01)
A61K 9/54 (2006.01)
A61K 47/34 (2017.01)
A61P 7/06 (2006.01)
A61K 31/4152 (2006.01)
A61K 9/20 (2006.01)
Priority
US 915761 P 03.05.2007
US 947731 P 03.07.2007
Divided from
EP15199469
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. Jul 15, 2026

    Change

    Published in Swissreg on 15.07.2026

  3. Dec 24, 2025

    Change

    Published in Swissreg on 24.12.2025

  4. Dec 10, 2025

    Change

    Published in Swissreg on 10.12.2025

  5. Sep 17, 2025

    Change

    Published in Swissreg on 17.09.2025

  6. Sep 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 01.09.2025

  7. Aug 13, 2025

    Change

    Published in Swissreg on 13.08.2025

  8. Mar 26, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 26.03.2025

Parties

Holder

Novartis Pharma AG

Lichtstrasse 35, 4056 Basel

Inventor

KAPSI, Shivakumar, G.

King Of Prussia, Pennsylvania, 19406, US

MULLER, Francis, X.

King Of Prussia, Pennsylvania, 19406, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.